BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 113.10K | 116.10K | 119.40K | 121.00K | 120.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 113.10K | 116.10K | 119.40K | 121.00K | 120.90K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 113.10K | 116.10K | 119.40K | 121.00K | 120.90K |
| SG&A Expenses | 767.00K | 780.00K | 749.80K | 614.70K | 611.20K |
| Depreciation & Amortization | 201.40K | 232.60K | 257.50K | 291.60K | 292.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.51M | 1.61M | 1.50M | 1.39M | 1.43M |
| Operating Income | -1.40M | -1.50M | -1.38M | -1.27M | -1.30M |
| Income Before Tax | -1.39M | -1.45M | -1.20M | -1.06M | -1.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.39 | -1.45 | -1.20 | -1.06 | -1.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.39M | -1.45M | -1.20M | -1.06M | -1.14M |
| EBIT | -1.40M | -1.50M | -1.38M | -1.27M | -1.30M |
| EBITDA | -1.39M | -1.49M | -1.37M | -1.26M | -1.29M |
| EPS Basic | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.15B | 352.25M | 344.65M | 337.05M | 334.59M |
| Average Diluted Shares Outstanding | 1.15B | 352.25M | 344.65M | 337.05M | 334.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |